PRAMEF12: A Potential Drug Target and Biomarker for the PRAME Family

Target Name: PRAMEF12

NCBI ID: G390999

PRAMEF12

Other Name(s): PRAME family member 12 | PRA12_HUMAN

PRAMEF12: A Potential Drug Target and Biomarker for the PRAME Family

The PRAME (Proteasome-Resident Membrane-Binding proteins) family consists of 12 member proteins that are involved in various cellular processes, including protein degradation, intracellular signaling, and cell survival. PRAMEF12, a member of the PRAME family, has been identified as a potential drug target and biomarker for various diseases.

The PRAME family plays a crucial role in the regulation of protein homeostasis, a process that involves the degradation of damaged or unnecessary proteins to maintain cellular order. The PRIME family is involved in this process by forming a covalent complex with the 尾-sheet of a target protein, which in turn promotes the formation of a covalent complex with the 纬-secretase complex. This covalent complex then leads to the targeted protein's degradation via the 纬-secretase complex.

PRAMEF12, specifically, is known for its role in the regulation of the Virus yangtan virus (YTV)-induced cell death in the HeLa cell line. YTV is a member of the Ponezomib family, which also includes other viruses that cause cancer, such as SAF-A1 and HeLa cells. PRAMEF12 has been shown to regulate the YTV-induced cell death by activating the PROMPT signaling pathway, which involves the inhibition of the 纬-secretase complex.

In addition to its role in YTV-induced cell death, PRAMEF12 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as the regulation of cell cycle progression, angiogenesis, and autophagy.

The potential drug target for PRAMEF12 is related to the inhibition of the 纬-secretase complex, which is a known therapeutic target for various diseases, including cancer. The 纬-secretase complex is involved in the degradation of proteins that are involved in cellular signaling pathways , as well as the regulation of cellular processes that are important for cancer progression.

PRAMEF12 has been shown to be involved in the regulation of the 纬-secretase complex in various cellular processes, including the regulation of cell cycle progression and the regulation of angiogenesis. Therefore, PRAMEF12 may be a potential drug target for diseases that are related to the regulation of the 纬-secretase complex.

In addition to its potential drug target, PRAMEF12 also has the potential to serve as a biomarker for various diseases. The regulation of the 纬-secretase complex by PRAMEF12 is known to be involved in the regulation of cellular processes that are important for cancer progression. Therefore, changes in the level of PRAMEF12 expression or activity may be relevant biomarkers for the diagnosis or prognosis of various diseases associated with the regulation of the 纬-secretase complex.

In conclusion, PRAMEF12 is a member of the PRAME family that is involved in various cellular processes, including the regulation of protein homeostasis and the regulation of cellular processes that are important for cancer progression. The potential drug target for PRAMEF12 is related to the inhibition of the 纬-secretase complex, which is a known therapeutic target for various diseases. PRAMEF12 also has the potential to serve as a biomarker for various diseases associated with the regulation of the 纬-secretase complex. Further research is needed to fully understand the role of PRAMEF12 in cellular processes and its potential as a drug target and biomarker for various diseases.

Protein Name: PRAME Family Member 12

The "PRAMEF12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets